Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density

BJU International

Volumn 113, Issue 4, 2014, Pages 561-567

  Umbehr, Martin H ^a,b,d,e   Platz, Elizabeth A ^a,b,c   Peskoe, Sarah B ^a   Bhavsar, Nrupen A ^a   Epstein, Jonathan I ^b,c   Landis, Patricia ^b   Partin, Alan W ^b,c   Carter, H Ballentine ^b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

active surveillance; patient selection; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROTEIN BLOOD LEVEL;

ACTIVE SURVEILLANCE; PATIENT SELECTION; PSA;

AGED; AGED, 80 AND OVER; BIOPSY, LARGE-CORE NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PATIENT SELECTION; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84896392617     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12131     Document Type: Article

References (12)

1. Lawrentschuk N, Klotz L,. Active surveillance for low-risk prostate cancer: an update. Nat. Rev Urol 2011; 8: 312-320
2. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
3. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
4. Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012; 188: 2152-2157
5. Han JS, Toll AD, Amin A, et al. Low prostate-specific antigen and no gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 2012; 80: 883-888
6. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
7. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013; 111: 22-29
8. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451
9. Carter HB, Walsh PC, Landis P, Epstein JI,. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-1234
10. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB,. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183: 1779-1785
11. Corcoran NM, Casey RG, Hong MK, et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 2012; 110: 36-42
12. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-752